Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS)

Multiple Sclerosis and Related Disorders

Volumn 8, Issue , 2016, Pages 19-26

  Meissner, Axel ^a   Limmroth, Volker ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cardiovascular profile; Fingolimod; Multiple sclerosis (MS); Relapsing remitting

Indexed keywords

FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT;

ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; DRUG APPROVAL; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ELEVATED BLOOD PRESSURE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; MULTIPLE SCLEROSIS; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SINUS BRADYCARDIA; TACHYCARDIA; WORKFLOW; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HEART RATE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOPHYSIOLOGY;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; FINGOLIMOD HYDROCHLORIDE; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84964891801     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2016.04.002     Document Type: Review

References (46)

1. M. Bünemann, B. Brandts, D.M. zu Heringdorf, and et al. Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1-phosphate J. Physiol. 489 1995 701 707
2. M. Baruscotti, A. Bucchi, and D. Difrancesco Physiology and pharmacology of the cardiac pacemaker ('funny') current Pharmacol. Ther. 107 1 2005 59 79
3. A. Bayés de Luna, P. Coumel, and J.F. Leclercq Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases Am. Heart J. 117 1 1989 151 159
4. C. Beckmann, A. Rinne, C. Littwitz, and et al. G protein-activated (GIRK) current in rat ventricular myocytes is masked by constitutive inward rectifier current (I(K1)) Cell Physiol. Biochem. 21 2008 259 268
5. V. Brinkmann Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology Pharmacol. Ther. 115 1 2007 84 105
6. V. Brinkmann FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system Br. J. Pharmacol. 158 5 2009 1173 1182
7. V. Brinkmann, and et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat. Rev. Drug Discov. 9 2010 883 897
8. V. Brinkmann, A. Billich, T. Baumruker, and et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat. Rev. Drug Discov. 9 11 2010 883 897
9. S.A. Broadley, M.H. Barnett, M. Boggild, and et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective Part 1 Historical and established therapies. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists J. Clin. Neurosci. 21 11 2014 1835 1846
10. P.A. Calabresi, E.W. Radue, D. Goodin, and et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Neurol. 13 2014 545 556
11. J. Calkwood, B. Cree, H. Crayton, and et al. Impact of a switch to fingolimod versus staying on glatirameracetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial BMC Neurol. 26 14 2014 220
12. J. Chun, and H.P. Hartung Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin. Neuropharmacol. 33 2 2010 91 101
13. Chun and Brinkmann A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya) Discov. Med. 64 2011 213 228
14. J.A. Cohen, F. Barkhof, G. Comi, and et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N. Engl. J. Med. 362 5 2010 402 415
15. Cohen et al., Disease Long-term safety of fingolimod: An interim analysis of the LONGTERMS cohort; AAN 2015, Washington, USA; S4.006.
16. DiMarco, J.P., O'Conner, P., Cohen, J.A., et al., 2014. First-Dose effects of fingolimod: pooled safety data from three phase 3 studies. Mult. Scler., < http://dx.doi.org/10.1016/j.msard.2014.05.005 > (Publication stage: In Press Corrected Proof).
17. EMA-Press release 20 April 2012: European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya.
18. EU Community register of medicinal products for human use, Product information Gilenya < http://ec.europa.eu/health/documents/community-register/html/h677.htm >. (accessed February 2016).
19. M.S. Freedman, D. Selchen, D.L. Arnold, and et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations Can. J. Neurol. Sci. 40 2013 307 323
20. R. Gold, G. Comi, J. Palace, and et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study J. Neurol. 261 2014 267 276
21. D.R. Herr, and J. Chun Effects of LPA and S1P on the nervous system and implications for their involvement in disease Curr. Drug Targets 8 2007 155 167
22. B.L. Hughes, M. Cascione, K. McCague, and et al. Cardiac effects of fingolimod after first dose administration and therapy change in patients with multiple sclerosis Neurology 80 P01 2013 170
23. G. Izquierdo, P. O'Connor, X. Montalban, and et al. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis Mult. Scler. 20 7 2014 877 881
24. L. Kappos, P. O'Connor, E.W. Radue, and et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial Neurology 84 15 2015 1582 1591
25. L. Kappos, E.W. Radue, P. O'Connor, and et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N. Engl. J. Med. 362 2010 387 401
26. H.L. Kennedy, J.A. Whitlock, M.K. Sprague, L.J. Kennedy, T.A. Buckingham, and R.J. Goldberg Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy N. Engl. J. Med. 312 4 1985 24 193 197
27. B. Khatri, F. Barkhof, G. Comi, and et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomized extension of the TRANSFORMS study Lancet Neurol. 10 2011 520 529
28. L. Koyrakh, M.I. Roman, V. Brinkmann, and et al. The heart rate decrease caused by acute fty720 administration is mediated by the g protein-gated potassium channel i Am. J. Transplant. 5 2005 529 536
29. Limmroth, V., Haverkamp, W., Dechend, R., et al., 2015. Interim analysis of the START study - extensive electrocardiographic monitoring confirms the good cardiac safety profile of Fingolimod. ECTRIMS 2015. Barcelona, Poster EP1338
30. M. Maceyka, K.B. Harikumar, S. Milstien, and et al. Sphingosine-1-phosphate signaling and its role in disease Trends Cell Biol. 22 2012 50 60
31. B.J. McVerry, and J.G. Garcia Endothelial cell barrier regulation by sphingosine 1-phosphate J. Cell Biochem. 92 2004 1075 1085
32. M. Mehling, V. Brinkmann, J. Antel, and et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis Neurology 71 16 2008 1261 1267
33. B. Metzler, P. Gfeller, G. Wieczorek, and et al. Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure Int. Immunol. 20 5 2008 633 644
34. D. Meyer zu Heringsdorf, and K.H. Jakobs Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism Biochim. Biophys. Acta 1768 4 2007 923 940
35. A. Murakami, H. Takasugi, S. Ohnuma, and et al. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist Mol. Pharmacol. 77 4 2010 704 713
36. M. Ocker, B. Tackenberg, and H. Strik Fingolimod - Entwicklung von Signaltransduktionshemmern für die Ther. Mult. Skler. Nervenheilkd. 30 2011 345 349
37. Rote-Hand-Brief zu Gilenya® (Fingolimod) 25 January 2012: Strengere kardiovaskuläre Überwachung zu Beginn der Therapie mit Gilenya® (Fingolimod) bei Patienten mit schubförmig-remittierend verlaufender Multipler Sklerose. . (accessed February 2016).
38. Rote-Hand-Brief zu Gilenya® 26 April 2012: Aktualisierung der kardiovaskulären Überwachung zu Beginn der Therapie mit Gilenya® (Fingolimod) bei Patienten mit schubförmig-remittierender Multipler Sklerose. < http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2012/20120426.pdf >. (accessed February 2016).
39. Salomone Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools Br. J. Pharmacol. 153 1 2008 140 147
40. G. Sanna, J. Liao, E. Jo, and et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate J. Biol. Chem. 279 2004 13839 13848
41. P. Santangeli, and F.E. Marchlinski Ventricular ectopy as a modifiable risk factor for heart failure and death: "Déjà Vu All Over Again" may be a good thing J. Am. Colloid Cardiol. 66 2 2015 14 110 112 10.1016/j.jacc.2015.05.031
42. N. Scolding, D. Barnes, S. Cader, and et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis Pract. Neurol. 15 4 2015 273 279
43. Summary of product characteristics Gilenya, May 2015.
44. Uehata, and et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 389 6654 1997 990 994
45. E. Vanoli, F. Pentimalli, and G. Botto Vagomimetic Effects of Fingolimod: Physiology and Clinical Implications CNS Neurosci. Ther. 20 6 2014 496 502
46. D.P. Zipes, A.J. Camm, M. Borggrefe, and et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace 8 9 2006 746 837